2025 Q3 -tulosraportti
Vain PDF
113 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
23 370
Myynti
Määrä
319
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 500 | - | - | ||
| 4 | - | - | ||
| 100 | - | - | ||
| 9 000 | - | - |
Ylin
1,53VWAP
Alin
1,46VaihtoMäärä
0,2 132 768
VWAP
Ylin
1,53Alin
1,46VaihtoMäärä
0,2 132 768
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 29.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenNice close today, but on relatively low volume, if we soon get above 1.65-1.7 with good volume backing us, we can look forward to some green days where we move up towards the next "recent high" around 2 kr,-
·1 päivä sittenSTENOCARE A/S positions itself as First-Mover Advantage in France with strategic partnership, product filing and national distribution partnership Summary STENOCARE enters the French cannabis market today at 08:00 ∙ News overview (AI) STENOCARE has entered into a strategic partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to position itself in the French market for medical cannabis, which is expected to be permanently legalized in 2026. They have submitted a regulatory dossier for their ASTRUM 10-10 oil product with a view to potential reimbursement. This strategic move aims to secure early access to a significant European market, where Movianto handles nationwide logistics and distribution. STENOCARE has entered into a partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to enter the French market for medical cannabis. A regulatory dossier for STENOCARE's ASTRUM 10-10 oil product has been submitted to the French authorities with a view to potential reimbursement. France's market for medical cannabis is expected to transition to permanent legalization in 2026, following a pilot program from 2021-2025. Movianto, a leading pharmaceutical distributor, will handle nationwide logistics and pharmacy supply for STENOCARE in France. Independent analysts estimate that approximately 300,000 French patients could qualify for medical cannabis treatment under a permanent framework. https://news.cision.com/stenocare/r/stenocare-a-s-positions-for-first-mover-advantage-in-france-with-strategic-partnership--product-fili,c4305515·1 päivä sittenThere has been a press conference https://stenocare.com/investor-relations/announcements/86521D2D4C62313A/
·3 päivää sittenThe support at 1.3 withstood the attack on Thursday and Friday, and since then the price has reacted nicely upwards again. If we now get the fundamental support we need from Q4, then this could turn out really well going forward.- ·5.2.Remember to look at the volume before you panic, folks, the stock falls 10% on a trade of 2000 DKK.
·5.2.Agreed mojopete. I also hope that investors open their eyes to stenocare. 
·4.2.TECHNICAL ANALYSIS – 4/2/2026 Good morning everyone! I promised to provide an update on the technical analysis, and it's been a while since the last one. Honestly, there isn't a whole lot new to add. Please refer back to my post from January 7th, where I, among other things, wrote that I would like to see the price test the 1.7 DKK zone soon. Already on January 12th, the price hit 1.68 DKK and was immediately rejected. This leads me to the volume profile of the stock's entire history. If you pull it from start to finish, it looks like this: 👉 https://www.tradingview.com/x/PmZavU4v/ Zoomed in: 👉 https://www.tradingview.com/x/qKLEx8bZ/ It is clearly visible here that the stock has effectively been range-bound since the end of August 2025, if one disregards the two price deviations that also appear on the chart. Otherwise, the price moves very clearly up and down within this channel. My bias has not changed. I still assess that there is a higher probability of an upward breakout. • Resistance: 1.7 DKK • Support: 1.3 DKK If we lose 1.3 DKK, the next support is still 1.3 DKK (range low), and then around 1.0 DKK. Conversely, I still believe that a clear break above 1.7 DKK could lead to a very rapid upward move. Have a good day!·8.2.Correction: Next support is 1.1 DKK (range low) and not 1.3 DKK AGAIN... :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
113 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenNice close today, but on relatively low volume, if we soon get above 1.65-1.7 with good volume backing us, we can look forward to some green days where we move up towards the next "recent high" around 2 kr,-
- ·1 päivä sittenSTENOCARE A/S positions itself as First-Mover Advantage in France with strategic partnership, product filing and national distribution partnership Summary STENOCARE enters the French cannabis market today at 08:00 ∙ News overview (AI) STENOCARE has entered into a strategic partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to position itself in the French market for medical cannabis, which is expected to be permanently legalized in 2026. They have submitted a regulatory dossier for their ASTRUM 10-10 oil product with a view to potential reimbursement. This strategic move aims to secure early access to a significant European market, where Movianto handles nationwide logistics and distribution. STENOCARE has entered into a partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to enter the French market for medical cannabis. A regulatory dossier for STENOCARE's ASTRUM 10-10 oil product has been submitted to the French authorities with a view to potential reimbursement. France's market for medical cannabis is expected to transition to permanent legalization in 2026, following a pilot program from 2021-2025. Movianto, a leading pharmaceutical distributor, will handle nationwide logistics and pharmacy supply for STENOCARE in France. Independent analysts estimate that approximately 300,000 French patients could qualify for medical cannabis treatment under a permanent framework. https://news.cision.com/stenocare/r/stenocare-a-s-positions-for-first-mover-advantage-in-france-with-strategic-partnership--product-fili,c4305515·1 päivä sittenThere has been a press conference https://stenocare.com/investor-relations/announcements/86521D2D4C62313A/
- ·3 päivää sittenThe support at 1.3 withstood the attack on Thursday and Friday, and since then the price has reacted nicely upwards again. If we now get the fundamental support we need from Q4, then this could turn out really well going forward.
- ·5.2.Remember to look at the volume before you panic, folks, the stock falls 10% on a trade of 2000 DKK.·5.2.Agreed mojopete. I also hope that investors open their eyes to stenocare.
- ·4.2.TECHNICAL ANALYSIS – 4/2/2026 Good morning everyone! I promised to provide an update on the technical analysis, and it's been a while since the last one. Honestly, there isn't a whole lot new to add. Please refer back to my post from January 7th, where I, among other things, wrote that I would like to see the price test the 1.7 DKK zone soon. Already on January 12th, the price hit 1.68 DKK and was immediately rejected. This leads me to the volume profile of the stock's entire history. If you pull it from start to finish, it looks like this: 👉 https://www.tradingview.com/x/PmZavU4v/ Zoomed in: 👉 https://www.tradingview.com/x/qKLEx8bZ/ It is clearly visible here that the stock has effectively been range-bound since the end of August 2025, if one disregards the two price deviations that also appear on the chart. Otherwise, the price moves very clearly up and down within this channel. My bias has not changed. I still assess that there is a higher probability of an upward breakout. • Resistance: 1.7 DKK • Support: 1.3 DKK If we lose 1.3 DKK, the next support is still 1.3 DKK (range low), and then around 1.0 DKK. Conversely, I still believe that a clear break above 1.7 DKK could lead to a very rapid upward move. Have a good day!·8.2.Correction: Next support is 1.1 DKK (range low) and not 1.3 DKK AGAIN... :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
23 370
Myynti
Määrä
319
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 500 | - | - | ||
| 4 | - | - | ||
| 100 | - | - | ||
| 9 000 | - | - |
Ylin
1,53VWAP
Alin
1,46VaihtoMäärä
0,2 132 768
VWAP
Ylin
1,53Alin
1,46VaihtoMäärä
0,2 132 768
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 29.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
113 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 29.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenNice close today, but on relatively low volume, if we soon get above 1.65-1.7 with good volume backing us, we can look forward to some green days where we move up towards the next "recent high" around 2 kr,-
- ·1 päivä sittenSTENOCARE A/S positions itself as First-Mover Advantage in France with strategic partnership, product filing and national distribution partnership Summary STENOCARE enters the French cannabis market today at 08:00 ∙ News overview (AI) STENOCARE has entered into a strategic partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to position itself in the French market for medical cannabis, which is expected to be permanently legalized in 2026. They have submitted a regulatory dossier for their ASTRUM 10-10 oil product with a view to potential reimbursement. This strategic move aims to secure early access to a significant European market, where Movianto handles nationwide logistics and distribution. STENOCARE has entered into a partnership with Institut des Cannabinoïdes Médicaux Français (ICMF) to enter the French market for medical cannabis. A regulatory dossier for STENOCARE's ASTRUM 10-10 oil product has been submitted to the French authorities with a view to potential reimbursement. France's market for medical cannabis is expected to transition to permanent legalization in 2026, following a pilot program from 2021-2025. Movianto, a leading pharmaceutical distributor, will handle nationwide logistics and pharmacy supply for STENOCARE in France. Independent analysts estimate that approximately 300,000 French patients could qualify for medical cannabis treatment under a permanent framework. https://news.cision.com/stenocare/r/stenocare-a-s-positions-for-first-mover-advantage-in-france-with-strategic-partnership--product-fili,c4305515·1 päivä sittenThere has been a press conference https://stenocare.com/investor-relations/announcements/86521D2D4C62313A/
- ·3 päivää sittenThe support at 1.3 withstood the attack on Thursday and Friday, and since then the price has reacted nicely upwards again. If we now get the fundamental support we need from Q4, then this could turn out really well going forward.
- ·5.2.Remember to look at the volume before you panic, folks, the stock falls 10% on a trade of 2000 DKK.·5.2.Agreed mojopete. I also hope that investors open their eyes to stenocare.
- ·4.2.TECHNICAL ANALYSIS – 4/2/2026 Good morning everyone! I promised to provide an update on the technical analysis, and it's been a while since the last one. Honestly, there isn't a whole lot new to add. Please refer back to my post from January 7th, where I, among other things, wrote that I would like to see the price test the 1.7 DKK zone soon. Already on January 12th, the price hit 1.68 DKK and was immediately rejected. This leads me to the volume profile of the stock's entire history. If you pull it from start to finish, it looks like this: 👉 https://www.tradingview.com/x/PmZavU4v/ Zoomed in: 👉 https://www.tradingview.com/x/qKLEx8bZ/ It is clearly visible here that the stock has effectively been range-bound since the end of August 2025, if one disregards the two price deviations that also appear on the chart. Otherwise, the price moves very clearly up and down within this channel. My bias has not changed. I still assess that there is a higher probability of an upward breakout. • Resistance: 1.7 DKK • Support: 1.3 DKK If we lose 1.3 DKK, the next support is still 1.3 DKK (range low), and then around 1.0 DKK. Conversely, I still believe that a clear break above 1.7 DKK could lead to a very rapid upward move. Have a good day!·8.2.Correction: Next support is 1.1 DKK (range low) and not 1.3 DKK AGAIN... :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
23 370
Myynti
Määrä
319
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 500 | - | - | ||
| 4 | - | - | ||
| 100 | - | - | ||
| 9 000 | - | - |
Ylin
1,53VWAP
Alin
1,46VaihtoMäärä
0,2 132 768
VWAP
Ylin
1,53Alin
1,46VaihtoMäärä
0,2 132 768
Välittäjätilasto
Dataa ei löytynyt